Semaglutide vs BPC-157

A comprehensive, data-driven comparison of Semaglutide (Ozempic) and BPC-157 (Body Protection Compound-157). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.

Semaglutide
FDA Approved
Type 2 diabetes, chronic weight management, and MASH
Evidence
High
Avg. Weight Loss15%
Monthly Cost$1,000 - $1,400/mo
DosingWeekly
ManufacturerNovo Nordisk
BPC-157
Category 2 (pending reclassification)
Tissue healing and injury recovery
Evidence
Low
Monthly Cost$50 - $120/mo
DosingDaily

Side-by-Side Comparison

PropertySemaglutide
Ozempic, Wegovy
BPC-157
Body Protection Compound-157, PL 14736
FDA Status
FDA Approved
Category 2 (pending reclassification)
Category
Weight Loss
Recovery & Healing
Primary Use
Type 2 diabetes, chronic weight management, and MASH
Tissue healing and injury recovery
Weight Loss %
15%
N/A
Monthly Cost
$1,000 - $1,400/mo
$50 - $120/mo
Administration
Subcutaneous injection
Subcutaneous injection
Typical Dose
2.4mg weekly (Wegovy dose)
250-500mcg daily
Frequency
Weekly
Daily
Mechanism

GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow gastric emptying, and reduce appetite

Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth factors, and accelerates tissue repair

Common Side Effects
  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • +2 more
  • Injection site discomfort
  • Mild headache
  • Dizziness
  • Fatigue
Serious Side Effects
  • Thyroid C-cell tumors
  • Pancreatitis
  • Diabetic retinopathy complications
  • Acute kidney injury
  • +1 more
  • Unknown long-term effects
  • Potential hormone interactions
Evidence Quality
High
Low
Clinical Trial Phase
Approved
N/A

Key Differences

  • 1Semaglutide is FDA-approved, while BPC-157 is currently category 2 (pending reclassification).
  • 2Semaglutide has clinical weight loss data (15%), while BPC-157 is not primarily indicated for weight loss.
  • 3BPC-157 is generally more affordable ($50 - $120/mo) compared to Semaglutide ($1,000 - $1,400/mo).
  • 4Semaglutide is dosed weekly, while BPC-157 is daily.
  • 5Semaglutide has high-quality evidence, while BPC-157 has low-quality evidence.
  • 6They belong to different categories: Semaglutide (Weight Loss) vs BPC-157 (Recovery & Healing).

Which Is Better For...

SE

Semaglutide

Those seeking an FDA-approved treatment with established safety data

BP

BPC-157

More budget-friendly option with lower monthly costs

SE

Semaglutide

More convenient dosing schedule (weekly)

BP

BPC-157

Fewer commonly reported side effects

SE

Semaglutide

Stronger clinical evidence base to support its use

Cost Comparison

PeptideMonthly Cost RangeFDA StatusManufacturer
Semaglutide$1,000 - $1,400/mo
FDA Approved
Novo Nordisk
BPC-157$50 - $120/mo
Category 2 (pending reclassification)
Various research labs

Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.

Frequently Asked Questions

What is the main difference between Semaglutide and BPC-157?

Semaglutide works via GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow. BPC-157 works via Synthetic peptide derived from gastric juice protein that promotes angiogenesis, modulates growth. They differ in FDA approval status, efficacy data, and cost.

Which is more effective for weight loss, Semaglutide or BPC-157?

Semaglutide has demonstrated 15% average weight loss in clinical trials. BPC-157 is not primarily used for weight loss.

How much does Semaglutide cost compared to BPC-157?

Semaglutide typically costs $1,000 - $1,400/mo, while BPC-157 costs $50 - $120/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

Are Semaglutide and BPC-157 FDA approved?

Semaglutide is FDA-approved. BPC-157 is not FDA-approved (Category 2 (pending reclassification)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

What are the side effects of Semaglutide vs BPC-157?

Common side effects of Semaglutide include Nausea, Diarrhea, Vomiting. Common side effects of BPC-157 include Injection site discomfort, Mild headache, Dizziness. Always consult a healthcare provider about potential side effects.

Can I switch from Semaglutide to BPC-157?

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.

Learn More

Semaglutide Full Profile
Type 2 diabetes, chronic weight management, and MASH

Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. In August 2025, it received accelerated approval for MASH (metab...

View Full Semaglutide Guide
BPC-157 Full Profile
Tissue healing and injury recovery

BPC-157 is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. Although not FDA-approved, it has gained significant attention in research a...

View Full BPC-157 Guide

Other Popular Comparisons

Medical Disclaimer

The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Semaglutide and BPC-157 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.